US-based pharmaceutical company Celgene Corporation has reached an agreement to acquire Delinia for a consideration of $775m, which includes an initial payment of $300m and continent payments up to $475m upon achievement of certain development, regulatory and commercial milestones.
Both companies involved in the transaction are based in the US.
Celgene aims to expand its inflammation and immunology pipeline for the treatment of autoimmune disorders through the acquisition.
US-based synthetic biology company Intrexon Corporation has signed a definitive agreement to acquire GenVec.
Also based in the US, the target company is a developer of gene delivery technology.
Intexron expects the acquisition will help expand its gene delivery platform to target complex multi-gene disorders.